Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Read more at about DURIPANC at ClinicalTrials.gov NCT05927142 – “Combining anti-PD-L1 immune checkpoint inhibitor durvalumab ...

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...

Use of immune checkpoint inhibitor (ICI) therapy for cancer was associated with a significant reduction in actinic keratoses ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

A new study published in JAMA determined that the addition of sugemalimab to chemotherapy enhances overall and ...

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...